WO2022260479A1 - Composition d'extrait mixte de plantes médicinales pour améliorer l'environnement microbien intestinal - Google Patents

Composition d'extrait mixte de plantes médicinales pour améliorer l'environnement microbien intestinal Download PDF

Info

Publication number
WO2022260479A1
WO2022260479A1 PCT/KR2022/008228 KR2022008228W WO2022260479A1 WO 2022260479 A1 WO2022260479 A1 WO 2022260479A1 KR 2022008228 W KR2022008228 W KR 2022008228W WO 2022260479 A1 WO2022260479 A1 WO 2022260479A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
group
prebiotics
intestinal
licorice
Prior art date
Application number
PCT/KR2022/008228
Other languages
English (en)
Korean (ko)
Inventor
고성규
홍세향
Original Assignee
주식회사 케이랩
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 케이랩 filed Critical 주식회사 케이랩
Publication of WO2022260479A1 publication Critical patent/WO2022260479A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00—Processes
    • A23V2300/18—Fractionation

Definitions

  • the present invention is yellow baek, hyeonggae, gosam, licorice, maekmundong and It relates to a prebiotics composition comprising a mixed extract or a fraction thereof of dry yellow, a food and feed composition for improving intestinal function containing the composition, a use of the composition for improving intestinal function, and a method for improving intestinal function using the composition.
  • Probiotics are living microorganisms that can beneficially function by maintaining the balance of intestinal flora, and are known to have a variety of functions.
  • probiotics are known to have beneficial functions to the human body, such as inhibiting the growth of harmful bacteria through competition for intestinal nutrients and barrier attachment sites, activating immunity, and reducing lactose intolerance.
  • fructo-oligosaccharides are known.
  • Fructooligosaccharide is an oligosaccharide in the form of ⁇ -1, 2-linked fructose molecules to sugar and can be fermented by Lactobacillus and Bifidobacteria, so ingestion of FOS can increase Bifidobacterium and Lactobacillus species. It is known that it can
  • the present inventors have completed the present invention by discovering the herbal complex extract of the present invention as an active ingredient of the prebiotics composition and confirming its effect.
  • One object of the present invention is yellow baek, hyeonggae, gosam, licorice, maekmundong and It is to provide a prebiotics composition comprising a mixed extract or a fraction thereof of dry yellow.
  • Another object of the present invention is to provide a food composition for improving intestinal function comprising the prebiotics composition.
  • Another object of the present invention is to provide a feed composition for improving intestinal function comprising the prebiotics composition.
  • Another object of the present invention is to provide a use for improving intestinal function of the prebiotics composition.
  • Another object of the present invention is to provide a method for improving intestinal function comprising administering the prebiotics composition to a subject.
  • the prebiotics composition of the present invention can promote intestinal health by promoting the growth of beneficial bacteria in the intestine and inhibiting harmful bacteria in the intestine.
  • FIG. 1 is a schematic diagram showing a method for constructing an animal model (ABX) inhibiting intestinal microorganisms and an animal model (ABX+DNCB) with more intensified inhibition of intestinal microorganisms.
  • Figure 2 is a diagram showing the change in body weight of the normal group, ABX group, DNCB group, ABX + DNCB group, and KAJD oriental composite extract intake group (ABX + DNCB + KAJD).
  • Figure 3 is a diagram showing the change in dietary intake of the normal group, ABX group, DNCB group, ABX + DNCB group, and ABX + DNCB + KAJD group.
  • FIG. 4 is a diagram showing changes in blood levels in feces of the normal group, the ABX group, the DNCB group, the ABX+DNCB group, and the ABX+DNCB+KAJD group.
  • 5 is a diagram showing changes in the level of mucus in feces of the normal group, the ABX group, the DNCB group, the ABX+DNCB group, and the ABX+DNCB+KAJD group.
  • FIG. 6 is a diagram showing changes in blood and mucus levels in feces of the normal group, the ABX group, the DNCB group, the ABX+DNCB group, and the ABX+DNCB+KAJD group.
  • FIG. 7 and 8 are diagrams showing changes in intestinal length in the normal group, the ABX group, the DNCB group, the ABX+DNCB group, and the ABX+DNCB+KAJD group.
  • FIG. 9 is a diagram showing changes in the state of intestinal tissue in the normal group, the ABX group, the DNCB group, the ABX+DNCB group, and the ABX+DNCB+KAJD group.
  • 10 and 11 are diagrams showing changes in intestinal microorganisms in the normal group, the ABX group, the DNCB group, the ABX+DNCB group, and the ABX+DNCB+KAJD group.
  • One aspect of the present invention is yellow baek, hyeonggae, gosam, licorice, macmundong and Provided is a prebiotics composition comprising a mixed extract of dry yellow or a fraction thereof.
  • the mixed extract of Hwangbaek, Hyeonggae, Gosam, Licorice, Maemundong and Geonjihwang may be mixed with "KAJD” or "KHU-ATO-JIN-D".
  • the mixed extract may be an extract of a mixture of hwangbaek, hyeonggae, gosam, licorice, maekmundong, and geonhwang extract, and may also be a mixture of hwangbaek, hyeonggae, gosam, licorice, maemundong, or geonhwang extract.
  • yellow baek is a dried bark of the hwangbaek tree, and has a crude drug name Phellodendri Cortex and a scientific name Phellodendron wilsonii . It is characterized by its bitter taste and cold nature, and is known to be used for nerves, cystoscopy, colonoscopy, and cardiomyoscopy.
  • Hyeonggae ( ⁇ ) is a dried whole plant of Hyeonggae, a Lamiaceae plant, and has the herbal name Schizonepetae Spica and the scientific name Schizonepeta tenuifolia . It is characterized by its bitter taste and warm nature, and is known to act on menopause and liver cirrhosis, and to exhibit digestive and antibacterial effects.
  • gosam ( ⁇ ) is the root of the skin of gosam, and has the herbal name Sophorae Radix and the scientific name Sophora flavescens . It has a peculiar smell, is persistent, and is characterized by very bitter and cold weakness.
  • licorice ( ⁇ ) is dried roots or stems of licorice, and has the herbal name Glycyrrhizae Radix and the scientific name Glycyrrhiza glabra . It has a characteristic odor and a sweet taste. Licorice is known to harmonize the toxicity of all medicines so that the medicinal effects appear well, control the heat and morale of the books, improve the communication of all blood vessels, and strengthen muscles and bones.
  • Gaonhyeonhwang is a dried rhizome of Rehmanniae, a plant of the ginseng family, and has the crude drug name Radix Rehmanniae Exsiccat or Rehmanniae Radix, scientific name Rehmanniae Exsiccat or Rehmannia adj glutinosa . It is characterized by its sweet taste and cold nature, and has diuretic and hypoglycemic action, and is known to be used for uterine bleeding, menstrual disorders, constipation, and general weakness.
  • the hwangbaek, hyeonggae, goginseng, licorice, maekmundong, and geonhwang may be purchased and used commercially, or those collected or cultivated in nature may be used, but are not limited thereto.
  • extract refers to an extract obtained by extracting a mixture of yellow baek, myeonggae, gosam, licorice, coriander, and dry yellow, a dilution or concentrate of the extract, a dried product obtained by drying the extract, and a crude product of the extract It includes extracts of all formulations that can be formed using extracts themselves and extracts, such as extracts, purified products, or mixtures thereof.
  • the extracts of hwangbaek, hyeonggae, sorghum, licorice, rhubarb, and dried yellow can be extracted from various organs of natural, hybrid, and mutant plants, for example, roots, aerial parts, stems, leaves, flowers, fruit bodies, and fruit It can be extracted from plant tissue culture as well as from the skin.
  • Extracts or fractions of hwangbaek, hyeonggae, sorghum, licorice, mungmundong, and geonhwang have never been used for prebiotics purposes, and it was first identified by the present inventors as having prebiotics uses.
  • the mixture of yellow baek, hyeonggae, gosam, licorice, ginseng, and dried yellow is 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 to 1.5: 0.5 A weight ratio of 1.5:0.5 to 1.5, specifically a weight ratio of 0.7 to 1.3:0.7 to 1.3:0.7 to 1.3:0.7 to 1.3:0.7 to 1.3:0.7 to 1.3, more specifically 1:1:1:1:1:1 It may be included in a weight ratio of, but is not limited thereto.
  • the extract of the present invention may be extracted with at least one solvent selected from the group consisting of water, alcohol having 1 to 4 carbon atoms, and mixed solvents thereof by extracting a mixture of yellow baek, hyeonggae, gosam, licorice, coriander, and dried yellow, but is not limited thereto. don't
  • the method for extracting the mixture is not particularly limited, and can be extracted according to a method commonly used in the art.
  • Non-limiting examples of the extraction method include a hot water extraction method, an ultrasonic extraction method, a filtration method, a reflux extraction method, and the like, which may be performed alone or in combination of two or more methods.
  • the type of extraction solvent used to extract the mixture is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of the extraction solvent may include water, alcohol, or a mixed solvent thereof, and these may be used alone or in combination of one or more, and specifically, water may be used.
  • alcohol is used as a solvent, alcohol having 1 to 4 carbon atoms may be specifically used.
  • fraction refers to a product obtained by performing fractionation in order to separate a specific component or a specific component group from a mixture containing various components.
  • a fractionation method for obtaining the fraction is not particularly limited, and may be performed according to a method commonly used in the art.
  • the fractionation method include a solvent fractionation method performed by treating various solvents, an ultrafiltration fractionation method performed by passing an ultrafiltration membrane having a constant molecular weight cut-off value, and various chromatography (size, charge, hydrophobicity). or a chromatographic fractionation method that performs separation based on affinity), and a combination thereof.
  • a method of obtaining fractions from the extract by treating the extract obtained by extracting the maple leaves of the present invention with a predetermined solvent may be mentioned.
  • the type of fractionation solvent used to obtain the fraction is not particularly limited, and any solvent known in the art may be used.
  • the fractionation solvent include polar solvents such as water and alcohol having 1 to 4 carbon atoms; non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane; or mixed solvents thereof. These may be used alone or in combination of one or more, but are not limited thereto.
  • extract or fraction may be prepared and used in the form of a dry powder after extraction, but is not limited thereto.
  • Prebiotic or “Prebiotics” is used by microorganisms, including beneficial bacteria, to promote the growth or activity of microorganisms, thereby exhibiting beneficial effects on the health of the host. component can mean.
  • the prebiotic may be one that improves the intestinal microflora to exhibit a beneficial effect on the host's health, and reduces the level of blood in the stool, reduces the level of mucus, reduces the length of the intestine, and improves the intestinal microbiome by improving the intestinal tissue. It may be to improve the environment, but is not limited thereto.
  • "improvement of intestinal flora” may promote the growth or growth of beneficial bacteria in the intestine and inhibit the growth or growth of harmful bacteria in the intestine, and may mean maintaining the balance between beneficial bacteria and harmful bacteria in the intestine.
  • intestinal beneficial bacteria may collectively refer to microorganisms that have beneficial effects on the human body while inhabiting the intestines.
  • intestinal beneficial bacteria may include probiotics.
  • the “probiotics” may refer to microorganisms that have a good effect on health in the body, Lachnospiraceae , Rikenellaceae, Prevotellaceae , Acetobacter family ( Acetobacteraceae ) , Lactobacillaceae ( Lactobacillaceae ) ) , Lactobacillus , Firmicutes , Verrucomicrobia , Bifidobacterium , Akkermansia , and the like, but are not limited thereto.
  • the "intestinal harmful bacteria” may collectively refer to microorganisms that live in the intestine and have a detrimental effect on the human body , such as enteritis .
  • the probiotics may be Lactobacillus plantarum and/or Lactobacillus pentosus, but is
  • the prebiotics composition of the present invention may include a mixed extract of hwangbaek, myeonggae, gosam, licorice, kimmundong, and geonhwang, and the mixed extract is to include 0.001 to 80% by weight based on the weight of the total prebiotics composition It may, but is not limited thereto.
  • the bloody feces level, mucus level, and intestinal length were prolonged in the intestinal microbial inhibition group and the deep intestinal microbial inhibition group. It was confirmed that there was an effect of reducing, improving intestinal tissue, increasing beneficial bacteria in the intestine, and reducing harmful bacteria (FIGS. 4 to 11).
  • KAJD herbal mixture extract of the present invention improves the intestinal flora and the intestinal microbial environment.
  • Another aspect of the present invention provides a food composition for improving intestinal function comprising the prebiotics composition.
  • the prebiotics are as described in other embodiments.
  • improved intestinal function refers to any change in the state that improves or normalizes the overall function of the intestine, improves the intestinal flora, promotes the proliferation or growth of beneficial bacteria in the intestine, suppresses the proliferation or growth of harmful bacteria in the intestine, balances beneficial and harmful bacteria in the intestine It may contain any one or more of oils and fats.
  • Food-wise acceptable salts that can be included in the food composition of the present invention are useful acid addition salts formed from food-acceptable free acids or metal salts formed from bases.
  • inorganic acids and organic acids may be used as free acids.
  • Hydrochloric acid, sulfuric acid, hydrobromic acid, sulfurous acid, or phosphoric acid may be used as the inorganic acid
  • citric acid, acetic acid, maleic acid, fumaric acid, gluconic acid, methanesulfonic acid, or the like may be used as the organic acid.
  • an alkali metal salt or an alkaline earth metal salt, sodium, potassium or calcium salt may be used as the metal salt. However, it is not limited thereto.
  • the food composition of the present invention includes forms such as pills, powders, granules, precipitates, tablets, capsules or liquids, and the food to which the composition can be added includes, for example, various foods, such as beverages, There are chewing gum, tea, vitamin complexes, and health supplements.
  • ingredients that can be included in the food composition of the present invention other than containing the prebiotic composition of the present invention as an essential ingredient, there are no particular restrictions on other ingredients, and, like conventional foods, various herbal extracts, food additives, or natural carbohydrates etc. can be contained as an additional component.
  • the content of the active ingredient in the food composition may be appropriately determined depending on the purpose of use (prevention, improvement or therapeutic treatment). At this time, the content of the active ingredient included in the composition is not particularly limited thereto, but may include 0.0001% to 10% by weight, preferably 0.001% to 1% by weight, based on the total weight of the composition.
  • the food auxiliary additives may include food auxiliary additives common in the art, for example, flavoring agents, flavoring agents, coloring agents, fillers, stabilizers, and the like.
  • natural carbohydrates examples include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrins, cyclodextrins, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural flavors eg, rebaudioside A, glycyrrhizin, etc.
  • synthetic flavors sacharin, aspartame, etc.
  • the food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and fillers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, and the like may be contained.
  • it may contain fruit flesh for the manufacture of natural fruit juice, fruit juice beverages and vegetable beverages. These components may be used independently or in combination.
  • the health supplement may include health functional food and health food.
  • the health functional food is the same term as food for special health use (FoSHU), and is a medicine processed to efficiently display bioregulatory functions in addition to nutritional supply, and has high medical effect. means food.
  • “function (sex)” means to obtain useful effects for health purposes such as regulating nutrients for the structure and function of the human body or physiological functions.
  • Food containing the food composition of the present invention can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and components commonly added in the art during the preparation.
  • the formulation of the food may also be prepared without limitation as long as the formulation is recognized as a food.
  • the food composition of the present invention can be prepared in various types of formulations, and unlike general drugs, it has the advantage of not having side effects that may occur when taking drugs for a long time by using food as a raw material, and has excellent portability.
  • Another aspect of the present invention provides a feed composition for improving intestinal function comprising the prebiotics composition.
  • the prebiotics and intestinal function improvement are as described in other aspects.
  • the term "feed composition” may mean any natural or artificial diet, one meal, etc., or a component of the one meal for animals to eat, ingest, and digest, or suitable therefor, and is well known in the art. It can be manufactured in a variety of shapes.
  • the type of feed is not particularly limited, and feeds commonly used in the art may be used.
  • Non-limiting examples of the feed include vegetable feeds such as grains, root fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, meal or grain by-products; Animal feed such as proteins, inorganic materials, oils, mineral oils, oils, single cell proteins, zooplankton, or food may be mentioned. These may be used alone or in combination of two or more.
  • the animal is a concept including livestock and pets.
  • the feed composition of the present invention may further include a binder, an emulsifier, a preservative, etc. added to prevent quality deterioration, and amino acids, vitamins, enzymes, probiotics, flavors, and non-protein nitrogen added to increase efficacy It may further include compounds, silicate agents, buffers, coloring agents, extractants, oligosaccharides, and the like, and may further include feed mixtures and the like, but is not limited thereto.
  • Another aspect of the present invention provides a use of the prebiotics composition for improving intestinal function.
  • the extracts, fractions, and intestinal function improvement are as described in other embodiments.
  • the improvement of intestinal function may include, but is not limited to, improvement of intestinal flora.
  • Another aspect of the present invention provides a method for improving intestinal function comprising administering the prebiotics composition to a subject.
  • the prebiotics and intestinal function improvement are as described in other aspects.
  • improvement may refer to any action that improves or benefits intestinal function by administering a composition containing the extract or a fraction thereof of the present invention to a subject.
  • the term "administration” means introducing a composition containing the extract or a fraction thereof to a subject in an appropriate manner.
  • the administration route of the composition of the present invention may be administered through various oral or parenteral routes as long as it can reach the target tissue. Specifically, it may be an oral administration method, but is not limited thereto, and may be appropriately selected by those skilled in the art.
  • subject of the present invention may mean all animals, including humans, that are subject to intestinal function improvement.
  • the animal may be mammals such as cattle, horses, sheep, pigs, goats, camels, antelopes, dogs, and cats that require treatment for symptoms similar thereto, as well as humans, but are not limited thereto.
  • a subject requiring the composition of the present invention may be a human or a non-human subject, but is not limited thereto.
  • composition for improving intestinal function of the present invention can be administered in an amount effective in food science or feed science.
  • food science or feed science effective amount means an amount sufficient to improve intestinal function at a reasonable benefit/risk ratio applicable to food science or feed science, and the effective dose level depends on the type of subject, age, sex and composition. sensitivity, administration time, administration route, administration period, factors including materials used simultaneously, and other factors well known in the field of food or feed science.
  • the extract or a fraction thereof may be administered at a dose of 0.01 to 500 mg/kg per day, specifically 10 to 100 mg/kg, and the administration may be administered once a day or divided into several times. .
  • KAJD was manufactured by Han Poong Pharmaceutical (Jeonju, Korea) according to good manufacturing practices (GMP).
  • KAJD is Phellodendri Cortex , Schizonepetae Spica , Sophorae Radix , Licorice ( Glycyrrhizae Radix ), Liriopis Tuber ) and
  • the obtained powder was dissolved in negative water and used.
  • the effect of KAJD was confirmed by orally administering 200 mg/kg of KAJD herbal complex extract dissolved in drinking water to the group inhibiting intestinal microorganisms every day at the same time for 2 weeks.
  • Example 1 Intestinal microbial suppression animal model (ABX) and intestinal microbial suppression intensified animal model (ABX + DNCB) construction
  • ABX model In order to establish an animal model (ABX model) for inhibiting intestinal microbes, ampicillin, metronidazole, vancomycin, and neo Four types of antibiotics containing neomycin sulfate were mixed and fed for 7 days, and then fed with plain water every 3 days. Four types of antibiotics were induced to suppress intestinal microorganisms by self-supplying while gradually increasing the concentration for 4 weeks.
  • FIG. 1 the feeding and application methods for constructing the intestinal microbial suppression animal model (ABX model) and the intestinal microbial suppression intensified animal model (ABX + DNCB model) are schematically shown in FIG. 1.
  • KAJD herbal composite extract dissolved in drinking water was orally administered daily at the same time for 2 weeks (ABX+DNCB+KAJD) to the group with enhanced inhibition of intestinal microbes (ABX+DNCB).
  • ABX+DNCB+KAJD the group with enhanced inhibition of intestinal microbes
  • Example 3-1 Confirmation of improvement in blood stool level and condition in the intestine of KAJD
  • stool samples were collected from the normal group, the intestinal microbial suppression group (ABX), the intestinal microbial suppression enhanced group (ABX + DNCB), and the KAJD oriental medicine mixed extract administration group (ABX + DNCB + KAJD).
  • a Hemoccult kit was used to visually check inflammation or blood levels. At this time, when 2 drops of the Hemoccult kit solution were added to the stool sample, the higher the degree of blue color change, the more severe the degree of inflammation or bloody stool.
  • stool consistency was used by more than 3 people to score the degree of viscosity and blood confirmation of mouse stool.
  • the KAJD oriental medicine mixture extract reduced the length of the intestine, which was prolonged by inhibition of intestinal microorganisms.
  • intestines were collected from the normal group (Normal), intestinal microbial suppression group (ABX), intestinal microbial suppression enhanced group (ABX+DNCB), and KAJD oriental medicine mixed extract administration group (ABX+DNCB+KAJD).
  • Normal normal
  • ABX intestinal microbial suppression group
  • ABX+DNCB intestinal microbial suppression enhanced group
  • a part of the tissue was separated, fixed with 4% paraformaldehyde (PFA), and then paraffin sections were prepared using paraffin (Paraplast High Melt, Surgipath, Leica, Biosystem, The Netherlands).
  • the KAJD herbal mixture extract restored the function of the intestinal tissue, which had been deteriorated by the suppression of intestinal microorganisms.
  • Example 3-4 Confirmation of the effects of KAJD on increasing the proportion of beneficial bacteria and reducing the proportion of harmful bacteria in the intestine
  • feces collected from the normal group the intestinal microbial suppression group (ABX), the intestinal microbial suppression enhanced group (ABX+DNCB), and the KAJD oriental medicine mixed extract administration group (ABX+DNCB+KAJD) were tested. Changes in the number of microorganisms were observed through 16s rRNA metagenome sequencing.
  • the KAJD herbal mixture extract reduced the number of harmful bacteria in the intestine that had been increased by inhibiting intestinal microorganisms, increased the number of beneficial bacteria in the intestine, and restored the flora to a level similar to normal.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention se rapporte à une composition prébiotique comprenant un extrait mixte de Cortex phellodendri, de Schizonepeta tenuifolia, de Sophora flavescens, de Radix glycyrrhizae, de Liriope platyphylla et <i/> de Rehmannia glutinosa séchée, ou une fraction de ces dernières, à une composition alimentaire et d'alimentation pour améliorer la fonction intestinale, comprenant la composition, à l'utilisation de la composition pour améliorer la fonction intestinale et à un procédé pour améliorer la fonction intestinale à l'aide de la composition.
PCT/KR2022/008228 2021-06-10 2022-06-10 Composition d'extrait mixte de plantes médicinales pour améliorer l'environnement microbien intestinal WO2022260479A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2021-0075528 2021-06-10
KR1020210075528A KR20220166593A (ko) 2021-06-10 2021-06-10 생약 혼합 추출물의 장내 미생물 환경 개선용 조성물

Publications (1)

Publication Number Publication Date
WO2022260479A1 true WO2022260479A1 (fr) 2022-12-15

Family

ID=84426199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/008228 WO2022260479A1 (fr) 2021-06-10 2022-06-10 Composition d'extrait mixte de plantes médicinales pour améliorer l'environnement microbien intestinal

Country Status (2)

Country Link
KR (1) KR20220166593A (fr)
WO (1) WO2022260479A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170017176A (ko) * 2015-08-05 2017-02-15 (주)아모레퍼시픽 장 내 유산균 증가용 조성물 및 이를 이용한 유산균 생산 방법
KR101782268B1 (ko) * 2016-09-01 2017-09-28 경희대학교 산학협력단 생약 혼합 추출물을 포함하는 아토피 피부염의 치료용 조성물
CN108434369A (zh) * 2018-06-15 2018-08-24 吉林农业大学 治疗鸡大肠杆菌病的益生菌复方中药发酵液
CN109497558A (zh) * 2018-11-13 2019-03-22 南京中医药大学 苦参药渣多糖合生元及其制备方法与应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170017176A (ko) * 2015-08-05 2017-02-15 (주)아모레퍼시픽 장 내 유산균 증가용 조성물 및 이를 이용한 유산균 생산 방법
KR101782268B1 (ko) * 2016-09-01 2017-09-28 경희대학교 산학협력단 생약 혼합 추출물을 포함하는 아토피 피부염의 치료용 조성물
CN108434369A (zh) * 2018-06-15 2018-08-24 吉林农业大学 治疗鸡大肠杆菌病的益生菌复方中药发酵液
CN109497558A (zh) * 2018-11-13 2019-03-22 南京中医药大学 苦参药渣多糖合生元及其制备方法与应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HONG SE HYANG, KU JIN MO, KIM HYO IN, KIM TAI YOUNG, SEO HYE SOOK, SHIN YONG CHEOL, KO SEONG-GYU: "Topical Application of KAJD Attenuates 2,4-Dinitrochlorobenzene-Induced Atopic Dermatitis Symptoms Through Regulation of IgE and MAPK Pathways in BALB/C Mice and Several Immune Cell Types", FRONTIERS IN PHARMACOLOGY, vol. 10, 1 January 2019 (2019-01-01), pages 1097, XP093013831, DOI: 10.3389/fphar.2019.01097 *

Also Published As

Publication number Publication date
KR20220166593A (ko) 2022-12-19

Similar Documents

Publication Publication Date Title
WO2016122234A1 (fr) Composition d&#39;agent pour eau potable et aliment ayant pour effet d&#39;éliminer les odeurs associées à l&#39;urine d&#39;un animal de compagnie, comprenant un mélange d&#39;extraits végétaux en tant que principe actif
WO2019199094A1 (fr) Nouvelle souche de bifidobacterium longum ou de lactobacillus rhamnosus ayant pour effet de prévenir ou de traiter l&#39;obésité, et utilisation correspondante
WO2014189328A1 (fr) Composition anti-obésité contenant une poudre d&#39;extrait de feuille de miller lycium chinense et de la bétaïne comme principes actifs
WO2010137846A2 (fr) Composition pour accroître de la biodisponibilité de la saponine
WO2015002391A1 (fr) Composition présentant une fonction d&#39;atténuation du syndrome prémenstruel et des douleurs menstruelles
WO2021167350A1 (fr) Composition pour le traitement de trouble climatérique comprenant lactobacillus gasseri bnr17
WO2017183902A1 (fr) Composition contenant des extraits de artemisia capillaris, sanguisorba officinalis et curcuma longa et un agent antiviral, en tant que principes actifs, destinée à prévenir ou traiter une maladie du foie
WO2016190566A9 (fr) Composition pharmaceutique ou aliment naturel fonctionnel pour la prévention et le traitement de maladies métaboliques, contenant un extrait aqueux de pleurotus eryngii var. ferulae (pf.) en tant que principe actif
Bilan et al. Impacts on gut microbiota of rats with high-fat diet supplemented by herbs of Melissa officinalis, Lavandula angustifolia and Salvia officinalis
WO2019117654A1 (fr) Probiotiques pour inhiber et prévenir l&#39;évolution de maladies rénales et compositions pour inhiber et prévenir l&#39;évolution de maladies rénales les comprenant
WO2016076607A2 (fr) Composition pharmaceutique et aliment fonctionnel pour la santé, contenant un concentré de ginseng rouge avec un composé enrichi en composant k, pour la prévention et le traitement du symptôme de la stéatose hépatique d&#39;origine non alcoolique
WO2018190501A1 (fr) Composition anti-inflammatoire contenant un extrait de pédoncule de fleur de ginseng
KR20090094619A (ko) 면역증강, 또는 세균성 장염이나 콕시듐증의 예방 또는치료용 조성물
WO2019050123A1 (fr) Composition alimentaire pour traiter l&#39;obésité ou l&#39;hyperlipidémie comprenant un extrait de fruit de terminalia chebula et un extrait de phyllanthus emblica
WO2020085799A1 (fr) Composition pharmaceutique pour la prévention ou le traitement d&#39;une maladie hépatique, comprenant un extrait de platycodon grandiflorum standardisé contenant de la sapopnine de platycodon grandiflorum ou un extrait de saponine de platycodon grandiflorum séparé par membrane et aliment fonctionnel de santé pour l&#39;amélioration de la fonction hépatique
WO2020139020A2 (fr) Kimchi pour la prévention ou le traitement de maladies associées à helicobacter pylori
WO2012064158A2 (fr) Composition comprenant des herbes médicinales fermentées pour le traitement du syndrome du côlon irritable
WO2022260479A1 (fr) Composition d&#39;extrait mixte de plantes médicinales pour améliorer l&#39;environnement microbien intestinal
WO2023003204A1 (fr) Composition anti-obésité contenant un extrait de rosa davurica en tant que principe actif
WO2018008999A1 (fr) Composition comprenant un extrait d&#39;aster koraiensis ou une fraction de ce dernier en tant que principe actif servant à la régulation de la glycémie et à la prévention ou au traitement du diabète
WO2018030650A1 (fr) Composition anti-obésité contenant un extrait de feuilles de chrysanthème en tant que principe actif
WO2014133276A1 (fr) Composition contenant, en tant que composants actifs, menispermum dauricum, un extrait de menispermum dauricum, un biofilm de menispermum dauricum, ou un extrait de liquide enzymatique de malt de menispermum dauricum pour prévenir ou traiter l&#39;anorexie
KR20090094617A (ko) 항균, 항염, 및 면역 증강용 조성물
WO2012134252A2 (fr) Composition pour le traitement du cancer du rein et aliment fonctionnel contenant un extrait de semence de cannabis
WO2015122728A1 (fr) Composition anti-tuberculose pour le traitement et la prévention de la tuberculose comprenant un extrait ou de melia azedarach l. ou un extrait de lobelia chinensis lour et des fractions de ceux-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22820606

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22820606

Country of ref document: EP

Kind code of ref document: A1